Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

CanaQuest Medical Corporation gets listed on THE OCMX™

The OCMX™ is pleased to announce the listing of CanaQuest Medical Corporation to its online portal which offers Investors and Advisors the ability to participate in this opportunity.




MISSISSAUGA, ON, September 15, 2020 /24-7PressRelease/ -- CanaQuest Medical Corporation is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade).
The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, at Western University, London, Ontario Canada.
The OCMX™ is pleased to announce the listing of CanaQuest Medical Corporation to its online portal which offers Investors and Advisors the ability to participate in this opportunity.
The OCMX™ has spent considerable time completing its due diligence on CanaQuest Medical Corporation and concluded that there is indeed a tremendous opportunity for Investors and Advisors.
The OCMX™ noted that CanaQuest Medical Corporation exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.
OPPORTUNITY HIGHLIGHTS
1. Based on the preclinical trial results, we believe that Mentanine® has several advantages compared to Epidiolex, for example the Mentanine® formula, manufacturing process and drug delivery significantly increases the efficacy of the CBD thus requiring a lower amount of CBD, for medication purposes, which significantly reduces the negative side effects associated with Epidiolex.
2. The synergistic effect of the formula which allows the drug to cross the Blood Brain Barrier will provide the opportunity for Mentanine® to treat numerous identified mental health issues other than those health conditions for which Epidiolex has been approved.
3. Epidiolex is currently the only CBD product approved by the US FDA. The product was approved in June 2018. For the first full fiscal year (2019) after the launch of Epidiolex, GW Pharma generated in excess of $290 Million in revenue from Epidiolex, primarily from sales in the US.
4. CanaQuest will initially focus on obtaining regulatory approval for Mentanine®, as there is a clear path for obtaining regulatory approval for this product. CanaQuest has a second product Mentabinol® that provides a safer alternative for the consumption of THC. Preclinical trial results demonstrated that this product provides a safer alternative for dealing with opioid addiction.
MANAGEMENT TEAM
Paul Ramsay, President & Director
Mr. Paul Ramsay has served as President of the Company since its founding in 2008 (formally appointed March 31, 2009). He has over 30 years of business development and management experience. He was the Co-founder and former CEO and VP Business Development of Cymat Corp, (TSX: CYM) with a market valuation over $150 million upon his resignation in 2002.
Richard Rusiniak, CEO & Director
Mr. Richard Rusiniak has served as Chief Executive Officer of the Company since its founding in 2008 (formally appointed March 31, 2009). He has over 35 years of management, design and process experience. He was the Co- founder and former President, CFO, and CTO of Cymat Corp (TSX: CYM) with a market valuation over $150 million upon his resignation in 2002.
Ross Eastley, CFO & Director
Mr. Ross Eastley has been the Chief Financial Officer of the Company since 2009. Prior to that, he was CEO for the Canadian Society of Immigration Consultants (CSIC) from 2006 – 2009 and he was formerly V P/Controller for Brandon University, Manitoba.
ABOUT THE OCMX™
The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.
The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.
Contact Us
The OCMX™
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: prosper@theocmx.com
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com
Latest News
Top News